Ziming Li

Final Analysis of the Neotorch Study: Perioperative Toripalimab in Combination with Chemotherapy for Patients with Stage Ⅱ/Ⅲ Resectable Non-Small Cell Lung Cancer.

BACKGROUND Interim analysis of the Neotorch study demonstrated significant benefit in event-free survival (EFS) and major pathological response (MPR) rate for perioperative toripalimab plus chemotherapy in patients with resectable Stage Ⅲ non-small cell lung cancer (NSCLC). Here, we report the final analysis results of...

Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

PURPOSE MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...

Overweight BMI compromises survival and correlates with aggressive phenotypes in early-onset but not late-onset rectal cancer patients

Abstract Background The incidence of early-onset colorectal cancer (EOCRC) is rising globally, presenting unique clinical challenges due to its aggressive nature compared to late-onset cases. While obesity is a known risk factor for carcinogenesis, its prognostic significance specifically on the EOCRC population remain...

Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial

SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.

Overall, SYS6010 shows a manageable safety profile and encouraging antitumor activity in previously treated, advanced NSCLC.

Deep and durable response to re-challenge with platinum-based therapy in a platinum-relapsed small cell lung cancer patient following Olvi-Vec oncolytic immunotherapy: a case report

The role of Olvi-Vec as an oncolytic immunotherapy for cancer treatment warrants additional study, and the clinical effect observed in this patient may be related to Olvi-Vec-mediated changes in the tumor microenvironment, potentially leading to platinum re-sensitization.

BAG3+ CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC

The BAG3+ CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.